Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenformin SCHEMBL8424 | 0.97 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2LMNAGAA | |
| Phenformin SCHEMBL12487086 | 0.97 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2LMNAGAA | |
| Phenformin SCHEMBL210008 | 0.95 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2LMNAGAA | |
| Phenformin SCHEMBL3487197 | 0.95 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2LMNAGAA | |
| Phenformin SCHEMBL1560339 | 0.95 | RAB9A (0.50) | NPC1RAB9ASMN1; SMN2LMNAGAA | |
| Phenformin SCHEMBL15669213 | 0.95 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2LMNAGAA | |
| Phenformin SCHEMBL28415756 | 0.89 | ALDH1A1 (0.57) | NPC1RAB9ASMN1; SMN2LMNAGAA | |
| SCHEMBL7838315 | 0.87 | L3MBTL1 (0.51) | NPC1RAB9AGAATAAR1CYP2D6 | |
| Phenformin SCHEMBL11691594 | 0.86 | MEN1 (0.47) | NPC1RAB9ASMN1; SMN2TAAR1CA12 | |
| Phenformin SCHEMBL11697477 | 0.86 | MEN1 (0.47) | NPC1RAB9ASMN1; SMN2TAAR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. (US) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073331-A1 | GUANIDINE COMPOUNDS AND USE THEREOF | PC, TFAM, PCK2 | NPC1 1592/4885RAB9A 2328/4885SMN1; SMN2 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.